Form D · Biotechnology

Transcode Therapeutics, Inc.

Boston, MA · CIK 0001829635

Offering snapshot reported Dec 12, 2024 · SEC filing

Reported sold
$8M
Offering amount: $8M
Investors reported
6
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 2, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 12, 2024Initial$8,000,000No comparison6SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$320K
Finders' fees
$0
Form D file number
021-531946
The Benchmark Company LLC acted as the exclusive placement agent for the Private Placement and the Company paid them a cash fee. Also, the Company engaged A.G.P./Alliance Global Partners as financial advisor and paid them an expense fee and a cash fee.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
The Benchmark Company LLC000022982
A.G.P./Alliance Global Partners000008361

Source: Form D, filed Dec 12, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Philippe Calais Director
Thomas A. Fitzgerald Director, Executive
Erik Manting Director
Magda Marquet Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
6 Liberty Square, #2382
Boston, MA, 02109